Glucose Health（GLUC）株式概要グルコース・ヘルス社は、水溶性食物繊維入り栄養飲料の処方、製造、マーケティング、販売に従事している。 詳細GLUC ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 過去1年間で株主の希薄化は大幅に進んだ US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $14M )すべてのリスクチェックを見るGLUC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.45762.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-635k1m2016201920222025202620282031Revenue US$1.1mEarnings US$117.7kAdvancedSet Fair ValueView all narrativesGlucose Health, Inc. 競合他社BonkSymbol: NasdaqCM:BNKKMarket cap: US$11.1mNatural Alternatives InternationalSymbol: NasdaqGM:NAIIMarket cap: US$15.6mPMGC HoldingsSymbol: NasdaqCM:ELABMarket cap: US$7.1mNatural Health TrendsSymbol: NasdaqCM:NHTCMarket cap: US$20.3m価格と性能株価の高値、安値、推移の概要Glucose Health過去の株価現在の株価US$0.4552週高値US$0.6752週安値US$0.02ベータ01ヶ月の変化22.47%3ヶ月変化9.28%1年変化354.85%3年間の変化16.73%5年間の変化-87.01%IPOからの変化-99.76%最新ニュースお知らせ • Jun 05Glucose Health, Inc. Announces Appointment of Gerry David as Chairman of Strategic Advisory BoardGlucose Health, Inc. announced the appointment of Gerry David as Chairman of its newly formed Strategic Advisory Board of Directors. In this role, Mr. David will work closely with the Company’s leadership team to help develop and execute a coordinated business development strategy aimed at expanding Glucose Health’s presence in the dietary fiber and functional beverage markets. Gerry David brought over 40 years of experience in driving successful corporate turnarounds. His most notable achievement came as CEO of NASDAQ-listed Celsius Holdings, Inc. (CELH), where he transformed a struggling beverage brand on the brink of failure into a thriving, global company. Under his leadership, Celsius (CELH) achieved five consecutive years of record revenues and increased shareholder value by 35 times. He spearheaded the company’s international expansion, establishing a subsidiary in Hong Kong, launching products across Asia, South America, Europe, and the Middle East, and setting up manufacturing facilities in Germany, China, and the United States. In recognition of his remarkable leadership, he was named one of only 25 Gold Winners in the prestigious CEO World Awards and honored as “The Leader” in the CEO of the Year category in 2016.お知らせ • Feb 05Glucose Health, Inc. announced that it has received $0.1 million in fundingOn February 4, 2026, Glucose Health, Inc. closed the transaction.お知らせ • Dec 06Glucose Health, Inc. announced that it has received $0.02 million in fundingOn December 5, 2025, Glucose Health, Inc. closed the transaction. The transaction included participation from two investors.お知らせ • Oct 29Glucose Health, Inc. Appoints Christopher J. Jemapete to Its Board of Directors, Effective October 29, 2025Glucose Health, Inc. announced a further strengthening of its Board of Directors with the appointment of Christopher J. Jemapete, effective October 29, 2025. Mr. Jemapete was an early strategic investor in Glucose Health, Inc. beginning in 2017 and continues to maintain a substantial equity position in the company. Mr. Jemapete brings three decades of experience in the financial services and securities industry to the Board of Directors of Glucose Health, Inc., having held senior roles with prominent Wall Street firms, including E.F. Hutton, Shearson Lehman Brothers, and Fidelity Investments. Mr. Jemapete concluded his professional career with a tenure at ALPS Distributors, Inc., located in Denver, Colorado, before his retirement in 2010. Since retiring, Mr. Jemapete has dedicated his efforts to identifying and supporting investment opportunities in the micro-cap sector of the equity markets. Through his deep research methodology, he has developed a comprehensive understanding of the operational and financial challenges faced by emerging companies—particularly in areas related to capital formation, financing structures, and the execution of strategic growth initiatives. As one of the earliest strategic investors in Glucose Health, Inc. Mr. Jemapete has participated in each of the Private Placements offered by Glucose Health, Inc. since 2019 and played an essential role in the successful raising of over $2 million in capital. His firm conviction in the mission of Glucose Health, Inc. —to deliver functional food and beverage products designed to address the growing public health challenges of obesity and diabetes—led to his decision today, to join the Company’s Board of Directors. Mr. Jemapete holds a Bachelor of Science degree in Marketing from Fairfield University in Fairfield, Connecticut, and completed a two-year graduate program at Adelphi University in Garden City, New York, earning certification as a Certified Financial Planner.お知らせ • Oct 23Glucose Health, Inc. Appoints Edmund “Ned” Burke to Its Board of DirectorsGlucose Health, Inc. announced the appointment of Edmund (Ned) Burke, a highly accomplished financial services executive, to its Board of Directors. With more than four decades of leadership experience at prominent investment firms including Pioneer Funds and Fidelity Investments, Mr. Burke brings exceptional financial acumen and strategic insight to the company’s leadership team. Mr. Burke most recently served as Chief Executive Officer of ALPS Distributors, Inc., where he played a pivotal role in the successful distribution of closed-end funds and exchange-traded funds (ETFs). Under his direction, ALPS expanded its services to include critical back-office accounting and transfer services for many of the nation’s top money management firms. During his tenure, Mr. Burke established and managed key relationships with notable organizations such as Select Sector SPDR Exchange Traded Funds, GE Investment Management, and Clough closed-end funds.His outstanding contributions to the financial services industry were recognized in 2016 when he received the NOVA Award from the National Investment Company Service Association, honoring his leadership and innovation in the securities sector. As CEO, Mr. Burke oversaw impressive growth at ALPS, expanding the firm’s Assets Under Management (AUM) from $15 million to $225 million, representing a compound annual growth rate of 19.79% over approximately 15 years. In 2005, he successfully negotiated the sale of ALPS to Lovell Minnick Partners, a private equity firm specializing in financial services investments. Later, in 2011, DST Systems, Inc. acquired ALPS after Mr. Burke had firmly established it as a leading player in the financial services industry. Mr. Burke’s extensive experience in building and scaling financial organizations will be invaluable as Glucose Health, Inc., continues to expand operations and enhance shareholder value. In addition to his new role at Glucose Health, Mr. Burke serves on the boards of several prominent money management firms, including Financial Investors Trust, Clough Funds, and Liberty All-Star Trust.Mr. Burke earned a Bachelor of Arts degree in Economics from the University of New Hampshire.お知らせ • Oct 22+ 2 more updatesGlucose Health, Inc. Announces the Appointment of Marc Hatch as Chief Financial Officer Effective October 20, 2025Glucose Health, Inc. announced the appointment of Marc Hatch as Chief Financial Officer effective October 20, 2025. Marc Hatch is a seasoned operations and marketing executive with decades of experience developing, expanding, and managing consumer-facing direct sales and B2B operations. Marc brings a demonstrated history of optimizing sales performance, controlling costs, and enhancing profitability within direct-response and performance-based marketing channels. He has directed large-scale, multi-faceted national campaigns across broadcast, digital, and direct-response platforms. Mr. Hatch also operates Media Funding Group, a private entity specializing in marketing finance, which has committed significant capital to accelerate the ramp-up of the GlucoDown® and Fiber Up® brands. Mr. Hatch is a graduate of the Central Washington University School of Business and Economics (formerly the School of Accounting and Business). Additionally, Murray Fleming has agreed to continue serving as Director alongside Mr. Schaftlein for a transition period to maintain administrative continuity following his previously announced resignation as the Company’s Chief Executive Officer and Chief Financial Officer, effective September 30, 2025.最新情報をもっと見るRecent updatesお知らせ • Jun 05Glucose Health, Inc. Announces Appointment of Gerry David as Chairman of Strategic Advisory BoardGlucose Health, Inc. announced the appointment of Gerry David as Chairman of its newly formed Strategic Advisory Board of Directors. In this role, Mr. David will work closely with the Company’s leadership team to help develop and execute a coordinated business development strategy aimed at expanding Glucose Health’s presence in the dietary fiber and functional beverage markets. Gerry David brought over 40 years of experience in driving successful corporate turnarounds. His most notable achievement came as CEO of NASDAQ-listed Celsius Holdings, Inc. (CELH), where he transformed a struggling beverage brand on the brink of failure into a thriving, global company. Under his leadership, Celsius (CELH) achieved five consecutive years of record revenues and increased shareholder value by 35 times. He spearheaded the company’s international expansion, establishing a subsidiary in Hong Kong, launching products across Asia, South America, Europe, and the Middle East, and setting up manufacturing facilities in Germany, China, and the United States. In recognition of his remarkable leadership, he was named one of only 25 Gold Winners in the prestigious CEO World Awards and honored as “The Leader” in the CEO of the Year category in 2016.お知らせ • Feb 05Glucose Health, Inc. announced that it has received $0.1 million in fundingOn February 4, 2026, Glucose Health, Inc. closed the transaction.お知らせ • Dec 06Glucose Health, Inc. announced that it has received $0.02 million in fundingOn December 5, 2025, Glucose Health, Inc. closed the transaction. The transaction included participation from two investors.お知らせ • Oct 29Glucose Health, Inc. Appoints Christopher J. Jemapete to Its Board of Directors, Effective October 29, 2025Glucose Health, Inc. announced a further strengthening of its Board of Directors with the appointment of Christopher J. Jemapete, effective October 29, 2025. Mr. Jemapete was an early strategic investor in Glucose Health, Inc. beginning in 2017 and continues to maintain a substantial equity position in the company. Mr. Jemapete brings three decades of experience in the financial services and securities industry to the Board of Directors of Glucose Health, Inc., having held senior roles with prominent Wall Street firms, including E.F. Hutton, Shearson Lehman Brothers, and Fidelity Investments. Mr. Jemapete concluded his professional career with a tenure at ALPS Distributors, Inc., located in Denver, Colorado, before his retirement in 2010. Since retiring, Mr. Jemapete has dedicated his efforts to identifying and supporting investment opportunities in the micro-cap sector of the equity markets. Through his deep research methodology, he has developed a comprehensive understanding of the operational and financial challenges faced by emerging companies—particularly in areas related to capital formation, financing structures, and the execution of strategic growth initiatives. As one of the earliest strategic investors in Glucose Health, Inc. Mr. Jemapete has participated in each of the Private Placements offered by Glucose Health, Inc. since 2019 and played an essential role in the successful raising of over $2 million in capital. His firm conviction in the mission of Glucose Health, Inc. —to deliver functional food and beverage products designed to address the growing public health challenges of obesity and diabetes—led to his decision today, to join the Company’s Board of Directors. Mr. Jemapete holds a Bachelor of Science degree in Marketing from Fairfield University in Fairfield, Connecticut, and completed a two-year graduate program at Adelphi University in Garden City, New York, earning certification as a Certified Financial Planner.お知らせ • Oct 23Glucose Health, Inc. Appoints Edmund “Ned” Burke to Its Board of DirectorsGlucose Health, Inc. announced the appointment of Edmund (Ned) Burke, a highly accomplished financial services executive, to its Board of Directors. With more than four decades of leadership experience at prominent investment firms including Pioneer Funds and Fidelity Investments, Mr. Burke brings exceptional financial acumen and strategic insight to the company’s leadership team. Mr. Burke most recently served as Chief Executive Officer of ALPS Distributors, Inc., where he played a pivotal role in the successful distribution of closed-end funds and exchange-traded funds (ETFs). Under his direction, ALPS expanded its services to include critical back-office accounting and transfer services for many of the nation’s top money management firms. During his tenure, Mr. Burke established and managed key relationships with notable organizations such as Select Sector SPDR Exchange Traded Funds, GE Investment Management, and Clough closed-end funds.His outstanding contributions to the financial services industry were recognized in 2016 when he received the NOVA Award from the National Investment Company Service Association, honoring his leadership and innovation in the securities sector. As CEO, Mr. Burke oversaw impressive growth at ALPS, expanding the firm’s Assets Under Management (AUM) from $15 million to $225 million, representing a compound annual growth rate of 19.79% over approximately 15 years. In 2005, he successfully negotiated the sale of ALPS to Lovell Minnick Partners, a private equity firm specializing in financial services investments. Later, in 2011, DST Systems, Inc. acquired ALPS after Mr. Burke had firmly established it as a leading player in the financial services industry. Mr. Burke’s extensive experience in building and scaling financial organizations will be invaluable as Glucose Health, Inc., continues to expand operations and enhance shareholder value. In addition to his new role at Glucose Health, Mr. Burke serves on the boards of several prominent money management firms, including Financial Investors Trust, Clough Funds, and Liberty All-Star Trust.Mr. Burke earned a Bachelor of Arts degree in Economics from the University of New Hampshire.お知らせ • Oct 22+ 2 more updatesGlucose Health, Inc. Announces the Appointment of Marc Hatch as Chief Financial Officer Effective October 20, 2025Glucose Health, Inc. announced the appointment of Marc Hatch as Chief Financial Officer effective October 20, 2025. Marc Hatch is a seasoned operations and marketing executive with decades of experience developing, expanding, and managing consumer-facing direct sales and B2B operations. Marc brings a demonstrated history of optimizing sales performance, controlling costs, and enhancing profitability within direct-response and performance-based marketing channels. He has directed large-scale, multi-faceted national campaigns across broadcast, digital, and direct-response platforms. Mr. Hatch also operates Media Funding Group, a private entity specializing in marketing finance, which has committed significant capital to accelerate the ramp-up of the GlucoDown® and Fiber Up® brands. Mr. Hatch is a graduate of the Central Washington University School of Business and Economics (formerly the School of Accounting and Business). Additionally, Murray Fleming has agreed to continue serving as Director alongside Mr. Schaftlein for a transition period to maintain administrative continuity following his previously announced resignation as the Company’s Chief Executive Officer and Chief Financial Officer, effective September 30, 2025.お知らせ • Sep 27+ 1 more updateGlucose Health, Inc. Announces Resignation of Murray Fleming as Chief Executive Officer, Effective September 30, 2025Glucose Health, Inc. announced that its Chief Executive Officer has resigned, effective September 30, 2025, for personal reasons. The resignation was not requested by the Company. Murray Fleming, the Company’s sole Director, will perform the functions of Chief Executive Officer and Chief Financial Officer in his capacity as Director to provide administrative continuity and will assist shareholders in identifying new officers. This service will continue until one of the following occurs: Permanent successors, if any, are appointed. The Company determines to wind down and cease operations. The Board takes further action with respect to officer appointments.お知らせ • Jul 09Glucose Health, Inc. Formulations Have Always Been Free of Artificial Colors & Synthetic Dyes--Our Competitors Are Only Playing Catch-UpGlucose Health, Inc. affirms that its brands, GlucoDown®? and Fiber Up®?, have always used only natural colors derived from vegetables such as beets and carrots-- never any artificial synthetic dyes. Unlike legacy competitors such as Metamucil®? (The Procter & Gamble Company, P&G), which have long relied on synthetic dyes like Yellow 6 and Red 40, Glucose Health, Inc. committed to nutritionally efficacious, clean-label formulation, from GlucoDown®? brand's inception in 2017 - more than eight years ago. Now, amid the regulatory shift under U.S. Health and Human Services Secretary Robert F. Kennedy Jr., much larger competitors are facing pressure to finally reformulate and catch-up with Glucose Health Inc. Artificial synthetic dyes have long been used by manufacturers to create visually appealing drinks for consumers. While natural coloring alternatives from vegetables have existed for decades, the low cost of synthetic dyes improves profit margins--particularly and often prioritized by management and shareholders of large companies. Glucose Health, Inc.'s natural coloring ingredients from vegetables cost small company significantly more but reflect the always science-first approach to formulation and dedication to transparency and consumer trust. In addition to excluding artificial synthetic dyes, GlucoDown™? and Fiber Up®? also contain no preservatives such as sodium benzoate, or fillers like silicon dioxide--both commonly found in competitor's products. Instead, drink mixes are formulated exclusively around 100% soluble dietary fiber and natural flavors, delivering a clean nutritional profile unmatched in the dietary fiber and diabetic nutrition categories. This science-based approach extends to patent-pending metabolic nutrition formulation underpinning GlucoDown®? & Fiber Up®?, which uniquely supports metabolic wellness, most importantly including balanced glucose and cholesterol levels.お知らせ • Apr 02Glucose Health, Inc. Announces Expansion of Fiber Up®? Brand - More Drink Mix Flavors and New Fiber Up®? GumdropsGlucose Health, Inc. announced the expansion of its innovative Fiber Up®? brand of soluble fiber supplements, just launched in November 2023, with the introduction of two new drink mix flavors plus a new product format of Fiber Up®? gumdrops - all to be available for purchase shortly via Amazon. The two new drink mix flavors, Fiber Up®? Tropical and Fiber Up®? Fruit Punch, are formulated to provide consumers with refreshing and delicious options to support metabolic health with soluble nutrition. These new Fiber Up®? flavors combine the clinically benefits of soluble fiber with delicious taste, making it easier for individuals to incorporate fiber into their daily routines. Tropical offers a burst of exotic fruit flavors, while Fruit Punch delivers a classic, fruity taste that consumers love. All Fiber Up®? drink mix supplements are nutritionally superior to the market leading brand, containing no fillers and only 100% soluble prebiotic fiber - and are better tasting! Fiber Up®? offers consumers a convenient and effective way to incorporate soluble fiber into their daily routine, supporting overall wellness and vitality. In addition to the two new Fiber Up®? drink mix flavors, Glucose Health, Inc. is launching Fiber Up®? Gumdrops, another convenient and enjoyable way for consumers to add soluble fiber to their diets. These delicious gumdrops will be perfect for on-the-go persons looking for a quick and tasty fiber boost. With Fiber Up®?Gumdrops, consumers will enjoy the benefits of soluble fiber in a fun, convenient and delicious format.お知らせ • Dec 08+ 1 more updateGlucose Health, Inc. Announces Availability of FIBER UpGlucose Health, Inc. confirmed the very successful launch of FIBER UP, its innovative new line-up of prebiotic soluble fiber infused drink mixes, during the month of November 2023, at Amazon. The FIBER UP brand has garnered impressive sales success in its first month at Amazon, selling many hundreds of units and earning accolades from consumers for its great taste and fiber functionality. FIBER UP represents Glucose Health, Inc.'s second successful launch of a prebiotic soluble fiber drink mix brand at Amazon, following the introduction of GLUCODOWN, the delicious fiber drink mix for healthy glucose levels, in 2018. Very encouragingly, the initial sales success of FIBER UP in November 2023, eclipses that of GLUCODOWN, at the time of its launch. FIBER UP is currently offered in two delicious flavors "Very Berry Tea" and "Strawberry," each providing a tasty and convenient way for consumers to boost their daily fiber intake - and more exciting FIBER UP flavors are on-the-way! In this regard, to support and grow the FIBER UP brand, Glucose Health, Inc. is pleased to confirm it has secured a fifth round of working capital from its core group of investors. Since fiscal 2019, the Company has successfully raised capital via the issuance of five series of convertible preferred shares (Series B through Series F) - each on favorable terms usually available only to corporations listed on NASDAQ or NYSE. FIBER UP and GLUCODOWN share a common foundation--the infusion of prebiotic soluble fiber scientifically demonstrated to deliver physiological benefits, into great tasting drink mixes. Backed by more than 100 clinical studies and nutritional investigations, the innovative prebiotic soluble fiber formulas of both FIBER UP and GL UCODOWN drink mixes set them apart as trusted solutions for consumers seeking good metabolic health and overall well-being.お知らせ • Jun 29Glucose Health, Inc. has withdrawn its IPO in the amount of $8.5 million.Glucose Health, Inc. has withdrawn its IPO in the amount of $8.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,125,000 Price\Range: $4 Discount Per Security: $0.32お知らせ • Jun 03Glucose Health, Inc. has filed an IPO in the amount of $30 million.Glucose Health, Inc. has filed an IPO in the amount of $30 million. Security Name: Units Security Type: Equity/Derivative Unit Transaction Features: Sponsor Backed Offeringお知らせ • Mar 11Glucose Health, Inc. announced that it has received $0.96 million in fundingOn March 9, 2021, Glucose Health, Inc. (OTCPK:GLUC) closed the transaction. The transaction included participation from 10 investors.お知らせ • Jan 28Glucose Health, Inc. Announces New 2-Pack GLUCODOWN® Raspberry # 1 at AmazonGlucose Health, Inc. announced that New GLUCODOWN® 2-Pack Raspberry arrived at Amazon last week and is already trending across Amazon.com as a # 1 New Release. Amazon affixes the # 1 New Release moniker to new products which are showing strong consumer interest in their category. In response to burgeoning demand by consumers for online shopping, accelerated by the pandemic, Amazon imposed limits on shipments of inventory to its fulfillment centers from its seller partners, including the company. The restrictions significantly reduced both the size and frequency of shipments to Amazon to satisfy orders for GLUCODOWN®. The company immediately appealed to Amazon, making the case the restrictions would inevitably result in GLUCODOWN® selling-out in just weeks. Following GLUCODOWN® Lemon and then Raspberry selling out and an urgent appeal to Amazon's leadership team, the company's inventory allotment at Amazon was substantially increased. 5,000+ containers have already shipped from the company's Rogers, Arkansas logistics partner and are at various stages of receiving in Amazon's inventory system. Additionally, replenishment shipments to Amazon are now proceeding relatively normally – a shipment of more than 1,000 containers is being readied for picked up by Amazon later this week.お知らせ • Oct 15Glucose Health, Inc. Announces Its GlucoDown® Is Expanding to 2,000 Walmart Pharmacies for 2021Glucose Health, Inc. announced that Soon it will be much easier and more convenient to buy GlucoDown® at Walmart. Beginning this month, in-store availability of GlucoDown® Diabetic Friendly Peach Tea Mix is expanding to more than 2,000 Walmart pharmacies for 2021 more GlucoDown® at more Walmart pharmacies nationwide than ever before. Walmart has stocked GlucoDown® Diabetic Friendly Peach Tea Mix in an economical 45 servings container since 2018. GlucoDown® is found in the Diabetic Supplies aisle of the pharmacy at Walmart, on a middle or upper shelf. GlucoDown® has gained a loyal and growing following at Walmart because it is a delicious tea mix considered better tasting than even some national iced tea brands, yet at the same time, provides a combination of important nutritional attributes not available from any other diabetic friendly beverage in America. GlucoDown® is enriched with a unique form of soluble fiber which slows absorption of dietary sugars and additionally contributes to improved digestive health. Dozens of clinical studies support the efficacy of the soluble fiber in GlucoDown®. GlucoDown® is enriched with an extract of Banaba Leaf (Lagerstroemia speciosa). The use of Banaba Leaf as a holistic remedy for healthy blood sugar has been documented in Ayurvedic medicine, considered to be the world's oldest health system, for thousands of years. The active ingredient in Banaba Leaf is corosolic acid, which was discovered by scientists in the 1940's. GlucoDown® is enriched with important micronutrients including, for example, Chromium Picolinate, which some clinical studies indicate supports the maintenance of blood sugar in a healthy normal range. Other important micronutrients in the GlucoDown® formula include Zinc, Manganese, Thiamine, Biotin and Vitamins B12 and B6. GlucoDown® Diabetic Friendly Tea Mix is sugar-free and decaffeinated. All flavorings are 100% natural with no sugar added. The tea in GlucoDown® is sourced from the finest quality tea plantations in India and is certified by Rainforest Alliance and Fairtrade International.お知らせ • Sep 24Glucose Health, Inc. Unveils GLUCODOWN® "Enhanced Water" Drink Mix Retail Packaging and 2020 Launch DateGlucose Health, Inc. unveiled its GLUCODOWN® Diabetic Friendly "enhanced water" drink mix consumer packaging. The new packaging (view at the link below) features the characteristic brilliant colors and graphics that are a hallmark of GLUCODOWN® branded products and which serve to create maximum visibility to consumers browsing retailer shelves and online. With its introduction in early 2018, GLUCODOWN® defined an entirely new market category of diabetic-adult nutritional beverage – the first ever fiber and micronutrient infused iced tea mix. Now, Glucose Health, Inc. has achieved another beverage industry first – the first ever fiber and micronutrient infused "enhanced water" nutritionally tailored for persons with pre and Type-2 diabetes. By specializing in producing delicious beverages that are nutritionally appropriate for the nation's 100+ million pre and Type-2 diabetics, GLUCODOWN® is uniquely positioned among all up & coming beverage start-up companies in America. Entering the "enhanced water" category presents the opportunity for GLUCODOWN® to expand its market reach beyond iced tea, into a second rapidly growing beverage industry segment in addition to iced tea. The "enhanced water" beverage category is calculated by Fortune Business Insights to grow to $18 billion in annual revenues by 2025. As both the consumer packaging and product formulas for GLUCODOWN® Diabetic Friendly drink mixes are now completed, an estimated December 2020 product launch date is within reach. Accordingly, the issuances of purchase orders for raw materials began on September 15, 2020 with the placement of the order of vitamins & minerals in Company history.お知らせ • Jun 20+ 1 more updateGlucose Health, Inc. announced that it expects to receive $0.3 million in fundingGlucose Health, Inc. (OTCPK:GLUC) announced that it will receive $300,000 in funding on June 17, 2020. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.株主還元GLUCUS Personal ProductsUS 市場7D1.9%6.1%0.8%1Y354.8%-11.9%24.2%株主還元を見る業界別リターン: GLUC過去 1 年間で-11.9 % の収益を上げたUS Personal Products業界を上回りました。リターン対市場: GLUC過去 1 年間で24.2 % の収益を上げたUS市場を上回りました。価格変動Is GLUC's price volatile compared to industry and market?GLUC volatilityGLUC Average Weekly Movement17.4%Personal Products Industry Average Movement7.6%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: GLUCの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: GLUCの 週次ボラティリティ は過去 1 年間で29%から17%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2007n/aMark Schaftleinwww.glucosehealthinc.comグルコース・ヘルス社は、水溶性食物繊維入り栄養飲料の処方、製造、マーケティング、販売を行っている。水溶性食物繊維入りの粉末アイスティーや、糖尿病予備軍や糖尿病患者向けのフレーバードリンクミックスなどを、北米で「GLUCODOWN」ブランドで提供している。旧社名はバイオソリューションズ社で、2014年11月にグルコースヘルス社に社名変更した。グルコースヘルス社は2007年に法人化され、アーカンソー州ベントンビルに本社を置いている。もっと見るGlucose Health, Inc. 基礎のまとめGlucose Health の収益と売上を時価総額と比較するとどうか。GLUC 基礎統計学時価総額US$13.85m収益（TTM）-US$357.03k売上高(TTM)US$1.11m0.0xP/Sレシオ0.0xPER（株価収益率GLUC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GLUC 損益計算書（TTM）収益US$1.11m売上原価US$1.00m売上総利益US$112.62kその他の費用US$469.65k収益-US$357.03k直近の収益報告Sep 30, 2022次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%GLUC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 22:02終値2026/06/12 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Glucose Health, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 05Glucose Health, Inc. Announces Appointment of Gerry David as Chairman of Strategic Advisory BoardGlucose Health, Inc. announced the appointment of Gerry David as Chairman of its newly formed Strategic Advisory Board of Directors. In this role, Mr. David will work closely with the Company’s leadership team to help develop and execute a coordinated business development strategy aimed at expanding Glucose Health’s presence in the dietary fiber and functional beverage markets. Gerry David brought over 40 years of experience in driving successful corporate turnarounds. His most notable achievement came as CEO of NASDAQ-listed Celsius Holdings, Inc. (CELH), where he transformed a struggling beverage brand on the brink of failure into a thriving, global company. Under his leadership, Celsius (CELH) achieved five consecutive years of record revenues and increased shareholder value by 35 times. He spearheaded the company’s international expansion, establishing a subsidiary in Hong Kong, launching products across Asia, South America, Europe, and the Middle East, and setting up manufacturing facilities in Germany, China, and the United States. In recognition of his remarkable leadership, he was named one of only 25 Gold Winners in the prestigious CEO World Awards and honored as “The Leader” in the CEO of the Year category in 2016.
お知らせ • Feb 05Glucose Health, Inc. announced that it has received $0.1 million in fundingOn February 4, 2026, Glucose Health, Inc. closed the transaction.
お知らせ • Dec 06Glucose Health, Inc. announced that it has received $0.02 million in fundingOn December 5, 2025, Glucose Health, Inc. closed the transaction. The transaction included participation from two investors.
お知らせ • Oct 29Glucose Health, Inc. Appoints Christopher J. Jemapete to Its Board of Directors, Effective October 29, 2025Glucose Health, Inc. announced a further strengthening of its Board of Directors with the appointment of Christopher J. Jemapete, effective October 29, 2025. Mr. Jemapete was an early strategic investor in Glucose Health, Inc. beginning in 2017 and continues to maintain a substantial equity position in the company. Mr. Jemapete brings three decades of experience in the financial services and securities industry to the Board of Directors of Glucose Health, Inc., having held senior roles with prominent Wall Street firms, including E.F. Hutton, Shearson Lehman Brothers, and Fidelity Investments. Mr. Jemapete concluded his professional career with a tenure at ALPS Distributors, Inc., located in Denver, Colorado, before his retirement in 2010. Since retiring, Mr. Jemapete has dedicated his efforts to identifying and supporting investment opportunities in the micro-cap sector of the equity markets. Through his deep research methodology, he has developed a comprehensive understanding of the operational and financial challenges faced by emerging companies—particularly in areas related to capital formation, financing structures, and the execution of strategic growth initiatives. As one of the earliest strategic investors in Glucose Health, Inc. Mr. Jemapete has participated in each of the Private Placements offered by Glucose Health, Inc. since 2019 and played an essential role in the successful raising of over $2 million in capital. His firm conviction in the mission of Glucose Health, Inc. —to deliver functional food and beverage products designed to address the growing public health challenges of obesity and diabetes—led to his decision today, to join the Company’s Board of Directors. Mr. Jemapete holds a Bachelor of Science degree in Marketing from Fairfield University in Fairfield, Connecticut, and completed a two-year graduate program at Adelphi University in Garden City, New York, earning certification as a Certified Financial Planner.
お知らせ • Oct 23Glucose Health, Inc. Appoints Edmund “Ned” Burke to Its Board of DirectorsGlucose Health, Inc. announced the appointment of Edmund (Ned) Burke, a highly accomplished financial services executive, to its Board of Directors. With more than four decades of leadership experience at prominent investment firms including Pioneer Funds and Fidelity Investments, Mr. Burke brings exceptional financial acumen and strategic insight to the company’s leadership team. Mr. Burke most recently served as Chief Executive Officer of ALPS Distributors, Inc., where he played a pivotal role in the successful distribution of closed-end funds and exchange-traded funds (ETFs). Under his direction, ALPS expanded its services to include critical back-office accounting and transfer services for many of the nation’s top money management firms. During his tenure, Mr. Burke established and managed key relationships with notable organizations such as Select Sector SPDR Exchange Traded Funds, GE Investment Management, and Clough closed-end funds.His outstanding contributions to the financial services industry were recognized in 2016 when he received the NOVA Award from the National Investment Company Service Association, honoring his leadership and innovation in the securities sector. As CEO, Mr. Burke oversaw impressive growth at ALPS, expanding the firm’s Assets Under Management (AUM) from $15 million to $225 million, representing a compound annual growth rate of 19.79% over approximately 15 years. In 2005, he successfully negotiated the sale of ALPS to Lovell Minnick Partners, a private equity firm specializing in financial services investments. Later, in 2011, DST Systems, Inc. acquired ALPS after Mr. Burke had firmly established it as a leading player in the financial services industry. Mr. Burke’s extensive experience in building and scaling financial organizations will be invaluable as Glucose Health, Inc., continues to expand operations and enhance shareholder value. In addition to his new role at Glucose Health, Mr. Burke serves on the boards of several prominent money management firms, including Financial Investors Trust, Clough Funds, and Liberty All-Star Trust.Mr. Burke earned a Bachelor of Arts degree in Economics from the University of New Hampshire.
お知らせ • Oct 22+ 2 more updatesGlucose Health, Inc. Announces the Appointment of Marc Hatch as Chief Financial Officer Effective October 20, 2025Glucose Health, Inc. announced the appointment of Marc Hatch as Chief Financial Officer effective October 20, 2025. Marc Hatch is a seasoned operations and marketing executive with decades of experience developing, expanding, and managing consumer-facing direct sales and B2B operations. Marc brings a demonstrated history of optimizing sales performance, controlling costs, and enhancing profitability within direct-response and performance-based marketing channels. He has directed large-scale, multi-faceted national campaigns across broadcast, digital, and direct-response platforms. Mr. Hatch also operates Media Funding Group, a private entity specializing in marketing finance, which has committed significant capital to accelerate the ramp-up of the GlucoDown® and Fiber Up® brands. Mr. Hatch is a graduate of the Central Washington University School of Business and Economics (formerly the School of Accounting and Business). Additionally, Murray Fleming has agreed to continue serving as Director alongside Mr. Schaftlein for a transition period to maintain administrative continuity following his previously announced resignation as the Company’s Chief Executive Officer and Chief Financial Officer, effective September 30, 2025.
お知らせ • Jun 05Glucose Health, Inc. Announces Appointment of Gerry David as Chairman of Strategic Advisory BoardGlucose Health, Inc. announced the appointment of Gerry David as Chairman of its newly formed Strategic Advisory Board of Directors. In this role, Mr. David will work closely with the Company’s leadership team to help develop and execute a coordinated business development strategy aimed at expanding Glucose Health’s presence in the dietary fiber and functional beverage markets. Gerry David brought over 40 years of experience in driving successful corporate turnarounds. His most notable achievement came as CEO of NASDAQ-listed Celsius Holdings, Inc. (CELH), where he transformed a struggling beverage brand on the brink of failure into a thriving, global company. Under his leadership, Celsius (CELH) achieved five consecutive years of record revenues and increased shareholder value by 35 times. He spearheaded the company’s international expansion, establishing a subsidiary in Hong Kong, launching products across Asia, South America, Europe, and the Middle East, and setting up manufacturing facilities in Germany, China, and the United States. In recognition of his remarkable leadership, he was named one of only 25 Gold Winners in the prestigious CEO World Awards and honored as “The Leader” in the CEO of the Year category in 2016.
お知らせ • Feb 05Glucose Health, Inc. announced that it has received $0.1 million in fundingOn February 4, 2026, Glucose Health, Inc. closed the transaction.
お知らせ • Dec 06Glucose Health, Inc. announced that it has received $0.02 million in fundingOn December 5, 2025, Glucose Health, Inc. closed the transaction. The transaction included participation from two investors.
お知らせ • Oct 29Glucose Health, Inc. Appoints Christopher J. Jemapete to Its Board of Directors, Effective October 29, 2025Glucose Health, Inc. announced a further strengthening of its Board of Directors with the appointment of Christopher J. Jemapete, effective October 29, 2025. Mr. Jemapete was an early strategic investor in Glucose Health, Inc. beginning in 2017 and continues to maintain a substantial equity position in the company. Mr. Jemapete brings three decades of experience in the financial services and securities industry to the Board of Directors of Glucose Health, Inc., having held senior roles with prominent Wall Street firms, including E.F. Hutton, Shearson Lehman Brothers, and Fidelity Investments. Mr. Jemapete concluded his professional career with a tenure at ALPS Distributors, Inc., located in Denver, Colorado, before his retirement in 2010. Since retiring, Mr. Jemapete has dedicated his efforts to identifying and supporting investment opportunities in the micro-cap sector of the equity markets. Through his deep research methodology, he has developed a comprehensive understanding of the operational and financial challenges faced by emerging companies—particularly in areas related to capital formation, financing structures, and the execution of strategic growth initiatives. As one of the earliest strategic investors in Glucose Health, Inc. Mr. Jemapete has participated in each of the Private Placements offered by Glucose Health, Inc. since 2019 and played an essential role in the successful raising of over $2 million in capital. His firm conviction in the mission of Glucose Health, Inc. —to deliver functional food and beverage products designed to address the growing public health challenges of obesity and diabetes—led to his decision today, to join the Company’s Board of Directors. Mr. Jemapete holds a Bachelor of Science degree in Marketing from Fairfield University in Fairfield, Connecticut, and completed a two-year graduate program at Adelphi University in Garden City, New York, earning certification as a Certified Financial Planner.
お知らせ • Oct 23Glucose Health, Inc. Appoints Edmund “Ned” Burke to Its Board of DirectorsGlucose Health, Inc. announced the appointment of Edmund (Ned) Burke, a highly accomplished financial services executive, to its Board of Directors. With more than four decades of leadership experience at prominent investment firms including Pioneer Funds and Fidelity Investments, Mr. Burke brings exceptional financial acumen and strategic insight to the company’s leadership team. Mr. Burke most recently served as Chief Executive Officer of ALPS Distributors, Inc., where he played a pivotal role in the successful distribution of closed-end funds and exchange-traded funds (ETFs). Under his direction, ALPS expanded its services to include critical back-office accounting and transfer services for many of the nation’s top money management firms. During his tenure, Mr. Burke established and managed key relationships with notable organizations such as Select Sector SPDR Exchange Traded Funds, GE Investment Management, and Clough closed-end funds.His outstanding contributions to the financial services industry were recognized in 2016 when he received the NOVA Award from the National Investment Company Service Association, honoring his leadership and innovation in the securities sector. As CEO, Mr. Burke oversaw impressive growth at ALPS, expanding the firm’s Assets Under Management (AUM) from $15 million to $225 million, representing a compound annual growth rate of 19.79% over approximately 15 years. In 2005, he successfully negotiated the sale of ALPS to Lovell Minnick Partners, a private equity firm specializing in financial services investments. Later, in 2011, DST Systems, Inc. acquired ALPS after Mr. Burke had firmly established it as a leading player in the financial services industry. Mr. Burke’s extensive experience in building and scaling financial organizations will be invaluable as Glucose Health, Inc., continues to expand operations and enhance shareholder value. In addition to his new role at Glucose Health, Mr. Burke serves on the boards of several prominent money management firms, including Financial Investors Trust, Clough Funds, and Liberty All-Star Trust.Mr. Burke earned a Bachelor of Arts degree in Economics from the University of New Hampshire.
お知らせ • Oct 22+ 2 more updatesGlucose Health, Inc. Announces the Appointment of Marc Hatch as Chief Financial Officer Effective October 20, 2025Glucose Health, Inc. announced the appointment of Marc Hatch as Chief Financial Officer effective October 20, 2025. Marc Hatch is a seasoned operations and marketing executive with decades of experience developing, expanding, and managing consumer-facing direct sales and B2B operations. Marc brings a demonstrated history of optimizing sales performance, controlling costs, and enhancing profitability within direct-response and performance-based marketing channels. He has directed large-scale, multi-faceted national campaigns across broadcast, digital, and direct-response platforms. Mr. Hatch also operates Media Funding Group, a private entity specializing in marketing finance, which has committed significant capital to accelerate the ramp-up of the GlucoDown® and Fiber Up® brands. Mr. Hatch is a graduate of the Central Washington University School of Business and Economics (formerly the School of Accounting and Business). Additionally, Murray Fleming has agreed to continue serving as Director alongside Mr. Schaftlein for a transition period to maintain administrative continuity following his previously announced resignation as the Company’s Chief Executive Officer and Chief Financial Officer, effective September 30, 2025.
お知らせ • Sep 27+ 1 more updateGlucose Health, Inc. Announces Resignation of Murray Fleming as Chief Executive Officer, Effective September 30, 2025Glucose Health, Inc. announced that its Chief Executive Officer has resigned, effective September 30, 2025, for personal reasons. The resignation was not requested by the Company. Murray Fleming, the Company’s sole Director, will perform the functions of Chief Executive Officer and Chief Financial Officer in his capacity as Director to provide administrative continuity and will assist shareholders in identifying new officers. This service will continue until one of the following occurs: Permanent successors, if any, are appointed. The Company determines to wind down and cease operations. The Board takes further action with respect to officer appointments.
お知らせ • Jul 09Glucose Health, Inc. Formulations Have Always Been Free of Artificial Colors & Synthetic Dyes--Our Competitors Are Only Playing Catch-UpGlucose Health, Inc. affirms that its brands, GlucoDown®? and Fiber Up®?, have always used only natural colors derived from vegetables such as beets and carrots-- never any artificial synthetic dyes. Unlike legacy competitors such as Metamucil®? (The Procter & Gamble Company, P&G), which have long relied on synthetic dyes like Yellow 6 and Red 40, Glucose Health, Inc. committed to nutritionally efficacious, clean-label formulation, from GlucoDown®? brand's inception in 2017 - more than eight years ago. Now, amid the regulatory shift under U.S. Health and Human Services Secretary Robert F. Kennedy Jr., much larger competitors are facing pressure to finally reformulate and catch-up with Glucose Health Inc. Artificial synthetic dyes have long been used by manufacturers to create visually appealing drinks for consumers. While natural coloring alternatives from vegetables have existed for decades, the low cost of synthetic dyes improves profit margins--particularly and often prioritized by management and shareholders of large companies. Glucose Health, Inc.'s natural coloring ingredients from vegetables cost small company significantly more but reflect the always science-first approach to formulation and dedication to transparency and consumer trust. In addition to excluding artificial synthetic dyes, GlucoDown™? and Fiber Up®? also contain no preservatives such as sodium benzoate, or fillers like silicon dioxide--both commonly found in competitor's products. Instead, drink mixes are formulated exclusively around 100% soluble dietary fiber and natural flavors, delivering a clean nutritional profile unmatched in the dietary fiber and diabetic nutrition categories. This science-based approach extends to patent-pending metabolic nutrition formulation underpinning GlucoDown®? & Fiber Up®?, which uniquely supports metabolic wellness, most importantly including balanced glucose and cholesterol levels.
お知らせ • Apr 02Glucose Health, Inc. Announces Expansion of Fiber Up®? Brand - More Drink Mix Flavors and New Fiber Up®? GumdropsGlucose Health, Inc. announced the expansion of its innovative Fiber Up®? brand of soluble fiber supplements, just launched in November 2023, with the introduction of two new drink mix flavors plus a new product format of Fiber Up®? gumdrops - all to be available for purchase shortly via Amazon. The two new drink mix flavors, Fiber Up®? Tropical and Fiber Up®? Fruit Punch, are formulated to provide consumers with refreshing and delicious options to support metabolic health with soluble nutrition. These new Fiber Up®? flavors combine the clinically benefits of soluble fiber with delicious taste, making it easier for individuals to incorporate fiber into their daily routines. Tropical offers a burst of exotic fruit flavors, while Fruit Punch delivers a classic, fruity taste that consumers love. All Fiber Up®? drink mix supplements are nutritionally superior to the market leading brand, containing no fillers and only 100% soluble prebiotic fiber - and are better tasting! Fiber Up®? offers consumers a convenient and effective way to incorporate soluble fiber into their daily routine, supporting overall wellness and vitality. In addition to the two new Fiber Up®? drink mix flavors, Glucose Health, Inc. is launching Fiber Up®? Gumdrops, another convenient and enjoyable way for consumers to add soluble fiber to their diets. These delicious gumdrops will be perfect for on-the-go persons looking for a quick and tasty fiber boost. With Fiber Up®?Gumdrops, consumers will enjoy the benefits of soluble fiber in a fun, convenient and delicious format.
お知らせ • Dec 08+ 1 more updateGlucose Health, Inc. Announces Availability of FIBER UpGlucose Health, Inc. confirmed the very successful launch of FIBER UP, its innovative new line-up of prebiotic soluble fiber infused drink mixes, during the month of November 2023, at Amazon. The FIBER UP brand has garnered impressive sales success in its first month at Amazon, selling many hundreds of units and earning accolades from consumers for its great taste and fiber functionality. FIBER UP represents Glucose Health, Inc.'s second successful launch of a prebiotic soluble fiber drink mix brand at Amazon, following the introduction of GLUCODOWN, the delicious fiber drink mix for healthy glucose levels, in 2018. Very encouragingly, the initial sales success of FIBER UP in November 2023, eclipses that of GLUCODOWN, at the time of its launch. FIBER UP is currently offered in two delicious flavors "Very Berry Tea" and "Strawberry," each providing a tasty and convenient way for consumers to boost their daily fiber intake - and more exciting FIBER UP flavors are on-the-way! In this regard, to support and grow the FIBER UP brand, Glucose Health, Inc. is pleased to confirm it has secured a fifth round of working capital from its core group of investors. Since fiscal 2019, the Company has successfully raised capital via the issuance of five series of convertible preferred shares (Series B through Series F) - each on favorable terms usually available only to corporations listed on NASDAQ or NYSE. FIBER UP and GLUCODOWN share a common foundation--the infusion of prebiotic soluble fiber scientifically demonstrated to deliver physiological benefits, into great tasting drink mixes. Backed by more than 100 clinical studies and nutritional investigations, the innovative prebiotic soluble fiber formulas of both FIBER UP and GL UCODOWN drink mixes set them apart as trusted solutions for consumers seeking good metabolic health and overall well-being.
お知らせ • Jun 29Glucose Health, Inc. has withdrawn its IPO in the amount of $8.5 million.Glucose Health, Inc. has withdrawn its IPO in the amount of $8.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,125,000 Price\Range: $4 Discount Per Security: $0.32
お知らせ • Jun 03Glucose Health, Inc. has filed an IPO in the amount of $30 million.Glucose Health, Inc. has filed an IPO in the amount of $30 million. Security Name: Units Security Type: Equity/Derivative Unit Transaction Features: Sponsor Backed Offering
お知らせ • Mar 11Glucose Health, Inc. announced that it has received $0.96 million in fundingOn March 9, 2021, Glucose Health, Inc. (OTCPK:GLUC) closed the transaction. The transaction included participation from 10 investors.
お知らせ • Jan 28Glucose Health, Inc. Announces New 2-Pack GLUCODOWN® Raspberry # 1 at AmazonGlucose Health, Inc. announced that New GLUCODOWN® 2-Pack Raspberry arrived at Amazon last week and is already trending across Amazon.com as a # 1 New Release. Amazon affixes the # 1 New Release moniker to new products which are showing strong consumer interest in their category. In response to burgeoning demand by consumers for online shopping, accelerated by the pandemic, Amazon imposed limits on shipments of inventory to its fulfillment centers from its seller partners, including the company. The restrictions significantly reduced both the size and frequency of shipments to Amazon to satisfy orders for GLUCODOWN®. The company immediately appealed to Amazon, making the case the restrictions would inevitably result in GLUCODOWN® selling-out in just weeks. Following GLUCODOWN® Lemon and then Raspberry selling out and an urgent appeal to Amazon's leadership team, the company's inventory allotment at Amazon was substantially increased. 5,000+ containers have already shipped from the company's Rogers, Arkansas logistics partner and are at various stages of receiving in Amazon's inventory system. Additionally, replenishment shipments to Amazon are now proceeding relatively normally – a shipment of more than 1,000 containers is being readied for picked up by Amazon later this week.
お知らせ • Oct 15Glucose Health, Inc. Announces Its GlucoDown® Is Expanding to 2,000 Walmart Pharmacies for 2021Glucose Health, Inc. announced that Soon it will be much easier and more convenient to buy GlucoDown® at Walmart. Beginning this month, in-store availability of GlucoDown® Diabetic Friendly Peach Tea Mix is expanding to more than 2,000 Walmart pharmacies for 2021 more GlucoDown® at more Walmart pharmacies nationwide than ever before. Walmart has stocked GlucoDown® Diabetic Friendly Peach Tea Mix in an economical 45 servings container since 2018. GlucoDown® is found in the Diabetic Supplies aisle of the pharmacy at Walmart, on a middle or upper shelf. GlucoDown® has gained a loyal and growing following at Walmart because it is a delicious tea mix considered better tasting than even some national iced tea brands, yet at the same time, provides a combination of important nutritional attributes not available from any other diabetic friendly beverage in America. GlucoDown® is enriched with a unique form of soluble fiber which slows absorption of dietary sugars and additionally contributes to improved digestive health. Dozens of clinical studies support the efficacy of the soluble fiber in GlucoDown®. GlucoDown® is enriched with an extract of Banaba Leaf (Lagerstroemia speciosa). The use of Banaba Leaf as a holistic remedy for healthy blood sugar has been documented in Ayurvedic medicine, considered to be the world's oldest health system, for thousands of years. The active ingredient in Banaba Leaf is corosolic acid, which was discovered by scientists in the 1940's. GlucoDown® is enriched with important micronutrients including, for example, Chromium Picolinate, which some clinical studies indicate supports the maintenance of blood sugar in a healthy normal range. Other important micronutrients in the GlucoDown® formula include Zinc, Manganese, Thiamine, Biotin and Vitamins B12 and B6. GlucoDown® Diabetic Friendly Tea Mix is sugar-free and decaffeinated. All flavorings are 100% natural with no sugar added. The tea in GlucoDown® is sourced from the finest quality tea plantations in India and is certified by Rainforest Alliance and Fairtrade International.
お知らせ • Sep 24Glucose Health, Inc. Unveils GLUCODOWN® "Enhanced Water" Drink Mix Retail Packaging and 2020 Launch DateGlucose Health, Inc. unveiled its GLUCODOWN® Diabetic Friendly "enhanced water" drink mix consumer packaging. The new packaging (view at the link below) features the characteristic brilliant colors and graphics that are a hallmark of GLUCODOWN® branded products and which serve to create maximum visibility to consumers browsing retailer shelves and online. With its introduction in early 2018, GLUCODOWN® defined an entirely new market category of diabetic-adult nutritional beverage – the first ever fiber and micronutrient infused iced tea mix. Now, Glucose Health, Inc. has achieved another beverage industry first – the first ever fiber and micronutrient infused "enhanced water" nutritionally tailored for persons with pre and Type-2 diabetes. By specializing in producing delicious beverages that are nutritionally appropriate for the nation's 100+ million pre and Type-2 diabetics, GLUCODOWN® is uniquely positioned among all up & coming beverage start-up companies in America. Entering the "enhanced water" category presents the opportunity for GLUCODOWN® to expand its market reach beyond iced tea, into a second rapidly growing beverage industry segment in addition to iced tea. The "enhanced water" beverage category is calculated by Fortune Business Insights to grow to $18 billion in annual revenues by 2025. As both the consumer packaging and product formulas for GLUCODOWN® Diabetic Friendly drink mixes are now completed, an estimated December 2020 product launch date is within reach. Accordingly, the issuances of purchase orders for raw materials began on September 15, 2020 with the placement of the order of vitamins & minerals in Company history.
お知らせ • Jun 20+ 1 more updateGlucose Health, Inc. announced that it expects to receive $0.3 million in fundingGlucose Health, Inc. (OTCPK:GLUC) announced that it will receive $300,000 in funding on June 17, 2020. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
